300. IgG4-related disease Clinical trials / Disease details
Clinical trials : 40 / Drugs : 47 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05728684 (ClinicalTrials.gov) | February 28, 2023 | 17/1/2023 | Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease | A Single-arm Study Sponsored by Investigators to Evaluate the Efficacy and Safety of CM310 Recombinant Humanized Monoclonal Antibody Injection in Patients With Recurrent IgG4-related Diseases | IgG4 Related Disease | Biological: CM310 | Beijing Friendship Hospital | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | N/A | NULL |